X
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
The collaboration aims to co-develop SGB-3908, an siRNA drug candidate targeting angiotensinogen for the treatment of hypertension. SGB-3908 is an IND-enabling stage siRNA drug developed based on SanegeneBio's proprietary LEAD™ (Ligand and Enhancer Assisted Delivery) platform.
Lead Product(s): SGB-3908
Therapeutic Area: Cardiology/Vascular Diseases Product Name: SGB-3908
Highest Development Status: IND EnablingProduct Type: Large molecule
Partner/Sponsor/Collaborator: Innovent Biologics
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Collaboration December 26, 2023
Details:
Through the collaboration with Orbit, Sanegene is looking to develop a portfolio of advanced RNAi based Therapies. Orbit’s proprietary technology enables the screening of large libraries of peptides using a combination of DNA encoded libraries and bead-based presentation.
Lead Product(s): RNAi-based Therapy
Therapeutic Area: Genetic Disease Product Name: Undisclosed
Highest Development Status: DiscoveryProduct Type: Large molecule
Partner/Sponsor/Collaborator: Orbit Discovery
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Collaboration January 05, 2023
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
